Apimostinel (GATE-202)

Phase 2 study coming soon: initiation in 2024

Gate Neurosciences is a clinical-stage biotechnology company using precision medicine to develop a new generation of therapies that enhance synaptic function for the 1 billion people globally suffering from brain health disorders.

Headquarters

1210 Waterway Blvd
Indianapolis, IN 46202
United States

Connect

Privacy Policy| Terms & Conditions

| Sitemap